Drug Type Small molecule drug |
Synonyms Pemigatinib (JAN/USAN/INN), IBI-375, INCB-054828 + [5] |
Target |
Mechanism FGFR1 antagonists(Fibroblast growth factor receptor 1 antagonists), FGFR2 antagonists(Fibroblast growth factor receptor 2 antagonists), FGFR3 antagonists(Fibroblast growth factor receptor 3 antagonists) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (17 Apr 2020), |
RegulationPriority Review (US), Breakthrough Therapy (US), Accelerated Approval (US), Orphan Drug (US), Orphan Drug (EU), Priority Review (CN), Orphan Drug (AU) |
Molecular FormulaC24H27F2N5O4 |
InChIKeyHCDMJFOHIXMBOV-UHFFFAOYSA-N |
CAS Registry1513857-77-6 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Chromosome 8p11 myeloproliferative syndrome | US | 26 Aug 2022 | |
Cholangiocarcinoma | CA | 26 Nov 2021 | |
Locally Advanced Cholangiocarcinoma | EU | 26 Mar 2021 | |
Locally Advanced Cholangiocarcinoma | IS | 26 Mar 2021 | |
Locally Advanced Cholangiocarcinoma | LI | 26 Mar 2021 | |
Locally Advanced Cholangiocarcinoma | NO | 26 Mar 2021 | |
Metastatic Cholangiocarcinoma | EU | 26 Mar 2021 | |
Metastatic Cholangiocarcinoma | IS | 26 Mar 2021 | |
Metastatic Cholangiocarcinoma | LI | 26 Mar 2021 | |
Metastatic Cholangiocarcinoma | NO | 26 Mar 2021 | |
FGFR2 fusion or rearranged Cholangiocarcinoma | JP | 23 Mar 2021 | |
FGFR2 positive Intrahepatic Cholangiocarcinoma | US | 17 Apr 2020 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Bile Duct Neoplasms | Phase 3 | CN | 11 May 2021 | |
Unresectable Intrahepatic Cholangiocarcinoma | Phase 3 | US | 03 Jun 2019 | |
Unresectable Intrahepatic Cholangiocarcinoma | Phase 3 | CN | 03 Jun 2019 | |
Unresectable Intrahepatic Cholangiocarcinoma | Phase 3 | JP | 03 Jun 2019 | |
Unresectable Intrahepatic Cholangiocarcinoma | Phase 3 | AT | 03 Jun 2019 | |
Unresectable Intrahepatic Cholangiocarcinoma | Phase 3 | BE | 03 Jun 2019 | |
Unresectable Intrahepatic Cholangiocarcinoma | Phase 3 | CA | 03 Jun 2019 | |
Unresectable Intrahepatic Cholangiocarcinoma | Phase 3 | DK | 03 Jun 2019 | |
Unresectable Intrahepatic Cholangiocarcinoma | Phase 3 | FI | 03 Jun 2019 | |
Unresectable Intrahepatic Cholangiocarcinoma | Phase 3 | FR | 03 Jun 2019 |
Phase 2 | 528 | platinum (Molecularly-Guided Therapy MGT) Category 1) | slqdcvkzbf(ewbgqdtjmd) = kztencwtsp lgyuapiczy (kynhmgtxth, gqrvymuayn - ajtwwynoiu) View more | - | 14 Jun 2024 | ||
platinum (Chemotherapy Category 1) | slqdcvkzbf(ewbgqdtjmd) = rdknjpxfgf lgyuapiczy (kynhmgtxth, bwvfqsajgp - nnlhuuyila) View more | ||||||
Phase 2 | Chromosome 8p11 myeloproliferative syndrome FGFR1 gene rearrangement | 47 | Pemigatinib 13.5 mg | fummueddqy(xjuhkgioad) = awmaiawfqq fkchrvvumg (zpvozgkayu ) View more | Positive | 14 May 2024 | |
Phase 2 | Solid tumor TP53 co-mutations | BAP1 alterations | molecular brake mutations | - | ciwwotfbtp(tormfmrfpe) = lhlyptfxdv lciwjjssey (kwxerelukw ) View more | - | 06 May 2024 | ||
Placebo | ciwwotfbtp(tormfmrfpe) = htegimypsq lciwjjssey (kwxerelukw ) View more | ||||||
Phase 1 | 8 | (Arm A (Ivosidenib, Cisplatin, Gemcitabine)) | ctlyflcotn(cqcdpksssr) = darqerhiwf xwyiknljkm (lrtppatgly, zjnzkanxpc - geyuycdeip) View more | - | 02 May 2024 | ||
(Arm B (Pemigatinib, Cisplatin, Gemcitabine)) | jwleoibqcq(nupllqwxlc) = xlrencihox ictrbdgfyk (kuxvdchmib, vzrudxcptj - sufbpeehqr) View more | ||||||
Phase 2 | 14 | Quality-of-Life Assessment+Pemigatinib | roluqcocrl(bkjbdydftg) = yigkzyxqsx krbqtcsezk (atxjenznbc, gtqfpknmxw - aglprwcywk) View more | - | 21 Feb 2024 | ||
Phase 2 | Metastatic urothelial carcinoma FGFR3 mutations | FGF/FGFR alterations | 260 | Pemigatinib 13.5 mg once daily continuously | plbqidfjrh(ahihemqusa) = mkjgfvtjfa ptaidxhwpp (fdiixaslfo, 10.9 - 26.7) View more | - | 01 Feb 2024 | |
Pemigatinib 13.5 mg once daily intermittently | plbqidfjrh(ahihemqusa) = tatxyqcofk ptaidxhwpp (fdiixaslfo, 15.5 - 32.7) View more | ||||||
FIGHT-202 (ASCO_GI2024) Manual | Not Applicable | Cholangiocarcinoma FGFR2 Mutation | 120 | oigcsqxqbk(fdmzzfjqql) = bxyfuzkqgh xjonynojuj (bmgcynfboj, 6.4 - 8.6) View more | Positive | 18 Jan 2024 | |
NCT04256980 (AACR2023) Manual | Phase 2 | 30 | sbgugnqrsz(qkrsjmidpb) = ydkahxqyrt zuhnzdpkzy (wtgtcfyspg, 15.2 - NC) View more | Positive | 14 Apr 2023 | ||
Phase 2 | 107 | (cohorts A) | vcifhhtgyi(uscujpvzde) = rmrvklulzk cjuygxobgx (hvbroclzyv ) | Positive | 14 Apr 2023 | ||
(cohorts B) | vcifhhtgyi(uscujpvzde) = ozfkhxzlig cjuygxobgx (hvbroclzyv ) | ||||||
Phase 2 | 263 | (Cohort A-ID: FGFR3 Mutations or Fusions) | mqeaixblhs(pflgfljnma) = vlczrhhbbq ylydoxztym (uonfffwmvh, kbumhwaovk - geomszxuqr) View more | - | 24 Mar 2023 | ||
(Cohort B-ID: All Other FGF/FGFR Alterations) | joxhbykwiy(ktwjncnsba) = pgrcpuypiy juvgegmcce (qflxcrafwt, ndgkuiinwe - luhzoasecr) View more |